Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:

NCT ID: NCT05430035 Not yet recruiting - Clinical trials for Gallbladder Adenocarcinoma

Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma

Start date: July 2022
Phase: Phase 2
Study type: Interventional

Gallbladder adenocarcinoma is a devastating disease associated with a poor prognosis. Gallbladder and other biliary cancers will be responsible for an estimated 11,980 new cases, and 4,090 deaths in the US during 2020. The 5-year survival for all patients with gallbladder cancer is 18%, however this plummets to 2% for patients with metastatic disease. Patients with gallbladder cancer frequently develop peritoneal recurrence, particularly after intra-operative bile spillage during cholecystectomy for incidentally discovered gallbladder malignancy. Once developed, peritoneal metastases are difficult to treat and result in significant morbidity and mortality. As a result, novel approaches that target peritoneal metastases are needed for this disease. Prophylactic use of heated intraperitoneal chemotherapy (HIPEC) has been explored or is under active investigation for numerous gastrointestinal malignancies, including colon, gastric, and appendiceal cancers. HIPEC has efficacy in gallbladder cancer patients with macroscopic peritoneal disease undergoing cytoreductive surgery (CRS)/HIPEC and has been associated with a survival advantage in a multi-institutional retrospective case series. Incidentally discovered gallbladder cancer is treated with central hepatectomy and portal lymphadenectomy, therefore a prophylactic HIPEC can be easily incorporated into the second operation performed as part of the standard of care. In this early phase clinical trial, we will explore the safety and feasibility of prophylactic HIPEC for gallbladder cancer in patients at high-risk of peritoneal recurrence. The primary endpoint is to assess feasibility of the prophylactic heated intraperitoneal chemotherapy (HIPEC) approach in gallbladder cancer. The primary endpoints include occurrence of intra-operative complications, technical challenges, 90-day postoperative morbidity and mortality, length of stay and readmission, which will be documented and compared with historical controls after follow-up.

NCT ID: NCT05419479 Not yet recruiting - Pancreatic Cancer Clinical Trials

Switch Maintenance in Pancreatic

Start date: November 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body. This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells. The names of the study drugs involved in this study are: - Domvanalimab (also known as AB154) - Zimberelimab (also known as AB122) - APX005M

NCT ID: NCT05419362 Recruiting - Gastric Cancer Clinical Trials

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Start date: April 7, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II, multicenter, open-label study to evaluate the antitumor activity, efficacy and safety of GEN-001 in combination with avelumab as a third line (3L) or greater line treatment which is not received the Standard of Care (SOC) for patients with PD-L1 positive advanced GC/Gastroesophageal Junction Adenocarcinoma who are not received cancer immunotherapy regimens as mono or combination therapy.

NCT ID: NCT05419349 Completed - Clinical trials for Adenocarcinoma of the Esophagogastric Junction

Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database

Start date: June 1, 2022
Phase:
Study type: Observational

Siewert type II adenocarcinoma of the esophagogastric junction (AEG) is an independent tumor type that differs from esophageal and gastric cancers. However, the staging system specific to Siewert type II AEG remains controversial. Moreover, the value of the total examined lymph nodes (TLNs) is still not considered for AEG staging. Hence, this study aimed to explore the optimal cutoff of TLN for Siewert type II AEG using the Surveillance, Epidemiology, and End Results (SEER) database, which can be a useful tool for determining the cancer staging

NCT ID: NCT05417386 Not yet recruiting - Pancreas Cancer Clinical Trials

FOLFIRINOX + NIS793 in Pancreatic Cancer

Start date: November 2022
Phase: Phase 1
Study type: Interventional

This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin), chemoradiation and surgery for people with metastatic pancreas adenocarcinoma. The drugs involved in this study are: - NIS793 - FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin) Other interventions include - chemoradiation - surgery.

NCT ID: NCT05415709 Recruiting - Clinical trials for Ovarian Endometrioid Adenocarcinoma

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Start date: July 1, 2022
Phase: Early Phase 1
Study type: Interventional

This phase I trial studies the side effects of hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery in treating patients with stage III or IV ovarian, fallopian tube or peritoneal cancer receiving chemotherapy before surgery. Hyperthermic intraepithelial chemotherapy involves the infusion of heated cytotoxic chemotherapy that circulates into the abdominal cavity at the time of surgery. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery may kill more tumor cells compared to usual care.

NCT ID: NCT05403242 Not yet recruiting - Clinical trials for Advanced Gastroesophageal Adenocarcinoma

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Start date: July 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study was a single-arm, open, multi-center Phase Ib/II clinical trial to observe and evaluate the efficacy and safety of RC48-ADC plus S-1 in first-line treatment of advanced gastroesophageal adenocarcinoma with moderate expression of HER2.

NCT ID: NCT05400304 Not yet recruiting - Lung Adenocarcinoma Clinical Trials

Preoperative CT-based Radiomics Combined With Intraoperative Frozen Section Prediction Model for Spread Through Air Space in Lung Adenocarcinoma

Start date: July 1, 2022
Phase:
Study type: Observational

a multifactorial model combining radiomics with frozen section analysis is a potential biomarker for assessing Spread Through Air Space during surgery, which can provide decision-making support to therapeutic planning for early-stage lung adenocarcinomas.

NCT ID: NCT05394740 Not yet recruiting - Clinical trials for Gastric Adenocarcinoma

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Start date: June 6, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single-arm, single-center Phase Ib/II study to exploratorily evaluate the tolerability, safety, and efficacy of regorafenib and nivolumab plus chemotherapy in patients with unresectable advanced/recurrent gastric/ gastroesophageal junction/esophageal adenocarcinoma.

NCT ID: NCT05393986 Not yet recruiting - Pancreatic Cancer Clinical Trials

Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors

Start date: June 1, 2022
Phase: Phase 1
Study type: Interventional

An Open-Label, Single-Arm, Dose-Exploration Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of CT048 in Subjects with Advanced Solid Tumors